Sitagliptin Sandoz Indications/Uses

Monotherapy: Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with 2 diabetes mellitus.
Combination with Metformin: Sitagliptin is indicated in patients with 2 diabetes mellitus to improve glycaemic control in combination with metformin as initial therapy or when the single agent alone, with diet and exercise does not provide adequate glycaemic control.
Combination with a Sulphonylurea: Sitagliptin is indicated in patients with 2 diabetes mellitus to improve glycaemic control in combination with sulphonylurea when treatment with the single agent alone, with diet and exercise does not provide adequate glycaemic control.
Combination with a PPARγ agonist: Sitagliptin is indicated in patients with 2 diabetes mellitus to improve glycaemic control in combination with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e. a thiazolidinedione) as initial therapy or when treatment with the single agent alone, with diet and exercise does not provide adequate glycaemic control.
Combination with Metformin and a Sulphonylurea: Sitagliptin is indicated in patients with 2 diabetes mellitus to improve glycaemic control in combination with metformin and a sulphonylurea when dual therapy with these agents, with diet and exercise does not provide adequate glycaemic control.
Combination with Metformin and a PPARγ agonist: Sitagliptin is indicated in patients with 2 diabetes mellitus to improve glycaemic control in combination with metformin and a PPARγ agonist (i.e. a thiazolidinedione) when dual therapy with these agents, with diet and exercise does not provide adequate glycaemic control.
Combination with Insulin: Sitagliptin is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in combination with insulin (with or without metformin).